Eagle Biosciences Announces the Launch of Calretinin ELISA Assay Kit

Nashua, NH, August 08, 2017 --(PR.com)-- Eagle Biosciences is proud to announce a new assay, the
Calretinin ELISA Assay Kit. The assay was developed and manufactured by DLD Diagnostika Gmbh in
cooperation with the Institute for Prevention and Occupational Medicine of the German Social Accident
Insurance of the Ruhr-University Bochum (IPA). DLD Diagnostika develops, markets and provides
scientific service for high quality innovative tests and research immunoassays. They have assays for
autoimmune disease, cardiovascular disease, cancer diseases, and renal dysfunction.

The Calretinin ELISA is the best commercially available assay for measuring the biomarker calretinin in
serum and plasma. It will aid in researchers who are exploring an earlier detection of mesothelioma. Dan
Keefe, President of Eagle Biosciences, continued, We are enthusiastic about what this assay might mean
for the future of cancer research, especially those cancers that develop from asbestos exposure.

The Eagle Calretinin ELISA kit is available in a convenient 1 plate or custom bulk sizes and is priced
very competitively. The assay is sensitive and specific and provides results in under 5 hours. Visit Eagle's
website, www.eaglebio.com, or call 866-411-8023 for more details.

Page 1/2
PR.com Press Release Distribution Terms of Use
Contact Information:
Eagle Biosciences, Inc.
Dan Keefe
617-419-2019
Contact via Email
www.eaglebio.com

Online Version of Press Release:

You can read the online version of this press release at: http://www.pr.com/press-release/725821

News Image:

Page 2/2
PR.com Press Release Distribution Terms of Use